This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Coast Guard Software Yard Accelerates Secure Application Development
Coast Guard’s infrastructure official shared how the effort strengthens application development and cybersecurity.
8m watch -
Navy CTO on the Service’s AI-First Push
The service is focused on increasing speed and scale for software development and AI.
7m watch -
Readiness Lessons From CIA's First Chief Wellbeing Officer
Former CIA Chief Wellbeing Officer Jennifer Posa discussed why workforce wellbeing is a strategic driver of mission success.
42m watch -
Air Force Software Official: AI Should Reuse Code, Not Rewrite It
CTO Kurt Jarvis explained how RAG, vector databases and DevSecOps guardrails help agencies safely integrate AI into coding.
7m watch